Phase 2b Study to Evaluate the Efficacy and Safety of GBR 830 in Adults With Moderate to Severe Atopic Dermatitis

Inclusion Criteria:

- Male or female subjects aged ≥18 years with physician diagnosis of atopic dermatitis
for >1 year as defined by American Academy of Dermatology Consensus Criteria.

- Atopic dermatitis involvement of ≥10% of body surface area and IGA score of ≥3 at
screening and baseline.

- EASI score of ≥12 at screening or ≥16 at baseline.

- IGA score of ≥3 at screening and baseline (on the 0 to 4 IGA scale, in which 3 is
moderate and 4 is severe)

- Baseline Pruritus Numerical Rating Scale (NRS) score for maximum itch intensity ≥3
over the previous 24 hours.

Exclusion Criteria:

- Pregnant or lactating women.

- Prior treatment with GBR 830

- Treatment with biologics

- Systemic corticosteroids, immunosuppressive/immunomodulatory drugs or phototherapy
within 4 weeks of baseline

- Active chronic or acute infection requiring systemic treatment